A variety of neuropeptides are involved in the central control of gastro- intestinal (GI) functions. Amongst these peptides (which are localized in CNS neurons) are cholecystokinin (CCK; CCK-8; CCK-(26-33)) and gastrin- releasing peptide (GRP-(1-27)). The role which these peptides play is linked to the mechanisms which regulate their biosynthesis and metabolism. Since the biosynthetic rates of peptide precursors are generally determined by cellular contents of their encoding mRNAs, and metabolic rates by the specific peptidases associated with their metabolism, insight into the mechanisms controlling CCK mRNA and GRP mRNA levels and CCK and GRP metabolism in neuronal systems can further elucidate the physiological roles of CCK and GRP ( and related peptides) in the brain with respect to regulation of GI tract function and control. Therefore, the central question of this project is: how are CCK mRNA and GRP mRNA levels and CCK and GRP metabolism regulated in neuronal systems? Our hypothesis is that gene expression and metabolic enzymes associated with CCK- and GRP-producing neurons can be affected by transmitters, neuropeptides and steroid hormones. Transmitters and peptides bind to membrane receptors and activate intracellular messenger systems, while steroid hormones have intracellular soluble receptors.
The specific aims are (1) to characterize which second messenger systems influence levels of CCK mRNA and GRP mRNA, levels of proteolytic enzymes and levels of CCK and GRP (including various forms); (2) to characterize which specific proteolytic enzymes are involved in the metabolism of CCK and GRP in cyto and in vivo; (3) which transmitters and neuropeptides are involved in regulating these effects, and (4) which steroid hormones regulate CCK mRNA and GRP mRNA levels and metabolic enzymes. To meet these aims, the regulation of CCK mRNA and GRP mRNA and metabolic enzymes will be studied in cyto in a clonal human neuroblastoma cell line (derived from autonomic nervous system) which has high levels of CCK and GRP gene expression secretes CCK upon stimulation and in vivo in the rat brain. By combining mRNA measurements, CCK and GRP levels and metabolic enzyme measurements we are very confident that we will be successful in determining how CCK and GRP are regulated in neuronal systems.

Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Li, Y; Duckles, S P (1993) Effect of age on vascular content of calcitonin gene-related peptide and mesenteric vasodilator nerve activity in the rat. Eur J Pharmacol 236:373-8
Li, Y J; Duckles, S P (1992) Effect of endothelium on the actions of sympathetic and sensory nerves in the perfused rat mesentery. Eur J Pharmacol 210:23-30
Friedman, D J; Krause, D N; Duckles, S P (1992) Complex prejunctional actions of the D2 dopamine agonists N-0923 and N-0924 in the rat tail artery. J Pharmacol Exp Ther 260:568-75
Li, Y J; Duckles, S P (1991) Effect of opioid receptor antagonists on vasodilator nerve actions in the perfused rat mesentery. Eur J Pharmacol 204:323-8
Li, Y J; Duckles, S P (1991) GABA agonists and omega conotoxin GVIA modulate responses to nerve activation of the perfused rat mesentery. Life Sci 48:2331-9
Massamiri, T; Duckles, S P (1991) Interactions of sigma and phencyclidine receptor ligands with the norepinephrine uptake carrier in both rat brain and rat tail artery. J Pharmacol Exp Ther 256:519-24
Li, Y J; Duckles, S P (1991) Differential effects of neuropeptide Y and opioids on neurogenic responses of the perfused rat mesentery. Eur J Pharmacol 195:365-72
Massamiri, T; Duckles, S P (1991) Sigma receptor ligands inhibit rat tail artery contractile responses by multiple mechanisms. J Pharmacol Exp Ther 259:22-9
Nguyen, K; Barrios, V; Duckles, S P (1991) Prejunctional effects of opioids in the perfused mesentery of the rat and rabbit: interactions with alpha 2-adrenoceptors. Life Sci 48:931-8
Massamiri, T; Duckles, S P (1990) Multiple sites of action of (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3PPP) in blood vessels. Eur J Pharmacol 190:295-303

Showing the most recent 10 out of 14 publications